28 july 2026 (Navroze Bureau) : Boston Scientific has highlighted the expanding role of pulsed field ablation (PFA) in the treatment of atrial fibrillation (AF) across the Asia-Pacific (APAC) region, as healthcare providers increasingly adopt advanced technologies to improve heart rhythm management.
The company said growing awareness, technological innovation and rising demand for minimally invasive cardiac procedures are driving the use of PFA in clinical practice.
What Is Pulsed Field Ablation?
Pulsed field ablation is an emerging technology used to treat atrial fibrillation, a common heart rhythm disorder that can increase the risk of stroke, heart failure and other cardiovascular complications.
Unlike traditional thermal ablation techniques that use heat or cold, PFA uses controlled electrical pulses to target abnormal heart tissue while aiming to minimise damage to surrounding structures.
Rising Adoption Across APAC
Boston Scientific noted that hospitals and cardiac specialists across the Asia-Pacific region are increasingly exploring PFA as part of their treatment options for patients with atrial fibrillation.
The technology is gaining attention because of its potential to improve procedural efficiency and patient outcomes.
Addressing a Growing Health Challenge
Atrial fibrillation is becoming more common across APAC due to ageing populations and the rising prevalence of cardiovascular risk factors such as hypertension, diabetes and obesity.
Early diagnosis and effective treatment are considered important for reducing complications and improving patients’ quality of life.
Innovation in Cardiac Care
The company emphasised that continued innovation in electrophysiology is helping physicians deliver more precise and patient-focused treatment.
Advances such as pulsed field ablation are expected to play an increasingly important role in the future of cardiac rhythm management.
Looking Ahead
As research and clinical experience with PFA continue to expand, experts expect the technology to become a more widely used option in the management of atrial fibrillation.
Healthcare providers will continue to evaluate its long-term safety, effectiveness and benefits compared with established treatment approaches.